231295-27-5

Basic information

• Product Name: diethyl 2-acetoxy-2-[6-chloro-2-(3-fluorobenzoyl)-1H-indol-3-yl]malonate
• Synonyms: diethyl 2-acetoxy-2-[6-chloro-2-(3-fluorobenzoyl)-1H-indol-3-yl]malonate
• CAS NO: 231295-27-5
• Molecular Weight: 489.885
• Mol File: 231295-27-5.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: diethyl 2-acetoxy-2-[6-chloro-2-(3-fluorobenzoyl)-1H-indol-3-yl]malonate(CAS DataBase Reference)
• NIST Chemistry Reference: diethyl 2-acetoxy-2-[6-chloro-2-(3-fluorobenzoyl)-1H-indol-3-yl]malonate(231295-27-5)
• EPA Substance Registry System: diethyl 2-acetoxy-2-[6-chloro-2-(3-fluorobenzoyl)-1H-indol-3-yl]malonate(231295-27-5)

Safety Data

• Hazardous Substances Data: 231295-27-5(Hazardous Substances Data)

Upstream product

• 231295-19-5 6-chloro-N-methoxy-N-methyl-1H-indole-2-carboxamide 
• 16732-75-5 6-chloro-1H-indole-2-carboxylic acid 
• 896137-74-9 6-chloro-1-(phenylsulfonyl)-1H-indole-2-carboxylic acid 
• 231295-53-7 6-chloro-1-(phenylsulfonyl)indole 
• 17422-33-2 6-chloroindole 
• 231295-26-4 (6-chloro-1H-indol-2-yl)(3-fluorophenyl)methanone 
• 127-09-3 sodium acetate 
• 105-53-3 diethyl malonate 

Downstream Products

• 231295-28-6 diethyl [6-chloro-2-(3-fluorobenzoyl)-1H-indol-3-yl]malonate 

Relevant articles and documents

Design, synthesis and structure-activity relationship studies of novel and diverse cyclooxygenase-2 inhibitors as anti-inflammatory drugs

Because of the pivotal role of cyclooxygenase (COX) in the inflammatory processes, non-steroidal anti-inflammatory drugs (NSAIDs) that suppress COX activities have been used clinically for the treatment of inflammatory diseases/syndromes; however, traditional NSAIDs exhibit serious side-effects such as gastrointestinal damage and hyper sensitivity owing to their COX-1 inhibition. Also, COX-2 inhibition-derived suppressive or preventive effects against initiation/proliferation/invasion/motility/recurrence/metastasis of various cancers/tumours such as colon, gastric, skin, lung, liver, pancreas, breast, prostate, cervical and ovarian cancers are significant. In this study, design, synthesis and structure-activity relationship (SAR) of various novel {2-[(2-, 3- and/or 4-substituted)-benzoyl, (bicyclic heterocycloalkanophenyl)carbonyl or cycloalkanecarbonyl]-(5- or 6-substituted)-1H-indol-3-yl}acetic acid analogues were investigated to seek and identify various chemotypes of potent and selective COX-2 inhibitors for the treatment of inflammatory diseases, resulting in the discovery of orally potent agents in the peripheral-inflammation model rats. The SARs and physicochemical properties for the analogues are described as significant findings. For graphical abstract: see Supplementary Material. (www.informahealthcare.com/enz)